Abstract
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Transfusion and Apheresis ScienceReferences
Jack H, Sloe D, Westerholm B, Inman WHW, Vessey MP, Shapiro S, Lewis G, Worcester J. Venous Thromboembolic disease and ABO blood type. Lancet 1969;i:539–542
Talbot S, Ryrie D, Walkley EJ, Langman MJS. ABO blood groups and venous thromboembolic disease. Lancet. 1970;i:1257–1259
Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep vein thrombosis within a defined urban population. J. Intern. Med. 1992;232:155–160
Salvati EA, Lachiewicz P. Thromboembolism following total hip-replacement arthroplasty. The efficacy of dextran-warfarin in prophylaxis. J. Bone Joint Surg. 1976;58-A:921–925
Koster T, Blann AD, Briët E, Vandenbroucke J, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345:152–155
Gill JC, Endress-Brooks J, Bauer PJ, Marks WJ Jr., Montgomery RR. The effect of ABO blood groups on the diagnosis of von Willebrand disease. Blood. 1987;69:1691–1695
Caekebeke-Peerlinck KMJ, Koster T, Briët E. Bleeding time, blood groups and von Willebrand factor. Br. J. Haematol. 1989;73:217–220
Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N. Engl. J. Med. 1994;331:1601–1606
Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, Hamilton PA. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N. Engl. J.Med. 1996;335:701–707
European Consensus Statement. Prevention of venous thromboembolism. Int. Angiol. 1992;11:151–159
Sikorski JM, Hampson WG, Staddon GE. The natural history and aetiology of deep vein thrombosis after hip replacement. J Bone Joint Surg. 1981;63-B:171–177
Nowak-Gottl U, Schaudin E, Hoffmann C, Eckhoff-Donovan S, Merthes N. Intraoperative clotting factor dilution and activated hemostasis in children with Ewinǵs sarcoma or osteosarcoma: a prospective longitudinal study. Haematologica. 1995;80(4):311–317
Menges T, Rupp D, van Lessen A, Hempelmann G. Measures for reducing the use of homologous blood. Effects on blood coagulation during total endoprothesis. Anaesthesist. 1992;41(19):27–33
Utada K, Matayoshi I, Sumi C, Itaya M, Miyawasaki H, Ito M, Tamura H, Mitsukuji I. Aprotinin 2 million KIU reduces perioperative blood loss in patients undergoing primary total hip replacement. Masui. 1997;46(1):77–82
Murkin JM, Shannon NA, Bourne RB, Rorabeck CH, Cruickshank M, Wyile G. Aprotinin decreases blood loss in patients undergoing revision or bilateral total hip arthroplasty. Anesth. Analg. 1995;80(2):343–348
